Kindred Biosciences, Inc. (KIN)
$9.25
+0.01 (+0.11%)
Rating:
Recommendation:
Neutral
| Symbol | KIN |
|---|---|
| Price | $9.25 |
| Beta | 1.315 |
| Volume Avg. | 1.51M |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 9.24-9.26 |
| 1y Target Est | - |
| DCF Unlevered | KIN DCF -> | |
|---|---|---|
| DCF Levered | KIN LDCF -> | |
| ROE | -31.62% | Strong Sell |
| ROA | -24.66% | Sell |
| Operating Margin | - | |
| Debt / Equity | 30.29% | Neutral |
| P/E | -9.09 | Strong Sell |
| P/B | 5.39 | Strong Buy |
Latest KIN news
About
Download (Excel)Dr. Richard Chin
Healthcare
Drug Manufacturers—Specialty & Generic
Nasdaq Capital Market
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.